Literature DB >> 30302219

Chronic lymphocytic leukemia: "The times they are a-changin".

Stefano Molica1.   

Abstract

Entities:  

Keywords:  CLL; leukemia; novel therapy

Year:  2017        PMID： 30302219      PMCID： PMC6171998          DOI： 10.2217/ijh-2017-0007

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  7 in total

1.  Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

Authors:  Bruce D Cheson; John C Byrd; Kanti R Rai; Neil E Kay; Susan M O'Brien; Ian W Flinn; Adrian Wiestner; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

2.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors:  Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

Review 3.  Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more.

Authors:  Januario E Castro; Thomas J Kipps
Journal:  Best Pract Res Clin Haematol       Date:  2016-08-20       Impact factor: 3.020

4.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

Authors:  Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

Review 5.  Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.

Authors:  Massimo Di Maio; Ethan Basch; Jane Bryce; Francesco Perrone
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

6.  Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Authors:  A R Mato; B T Hill; N Lamanna; P M Barr; C S Ujjani; D M Brander; C Howlett; A P Skarbnik; B D Cheson; C S Zent; J J Pu; P Kiselev; K Foon; J Lenhart; S Henick Bachow; A M Winter; A-L Cruz; D F Claxton; A Goy; C Daniel; K Isaac; K H Kennard; C Timlin; M Fanning; L Gashonia; M Yacur; J Svoboda; S J Schuster; C Nabhan
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

7.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Andrew D Zelenetz; Jacqueline C Barrientos; Jennifer R Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S Pristupa; Tadeusz Robak; Jeff P Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H Adewoye; Lyndah K Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen
Journal:  Lancet Oncol       Date:  2017-01-28       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.